<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286438</url>
  </required_header>
  <id_info>
    <org_study_id>PB2452-PT-CL-0004</org_study_id>
    <nct_id>NCT04286438</nct_id>
  </id_info>
  <brief_title>Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure</brief_title>
  <acronym>REVERSE-IT</acronym>
  <official_title>A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhaseBio Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhaseBio Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, prospective single-arm study of reversal of the&#xD;
      antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with&#xD;
      uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive&#xD;
      procedure.&#xD;
&#xD;
      Approximately 200 patients will be enrolled from approximately 200 centers in North America,&#xD;
      Europe, and Asia-Pacific regions, including mainland China. Patients with reported use of&#xD;
      ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible&#xD;
      for enrollment. These populations will be enrolled based on separate inclusion criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a Screening/Pre-treatment period, an on-site assignment to study&#xD;
      treatment and administration, a Follow-up visit on (Day 3+1 and Day 7±1) and a Final&#xD;
      Follow-up visit (Day 35±3). Infusion of PB2452 will be initiated on Day 1 and will continue&#xD;
      for approximately 16 hours for a total of 18 g.&#xD;
&#xD;
      On Day 1, subjects who meet all the inclusion criteria and none of the exclusion criteria&#xD;
      will receive an intravenous (IV) infusion comprised of an initial IV bolus of 6 grams (g)&#xD;
      infused over 10 minutes for rapid reversal, followed immediately by a 6g IV loading infusion&#xD;
      over 4 hours and then a 6 g IV maintenance infusion over 12 hours. This bentracimab (PB2452)&#xD;
      regimen is expected to provide immediate reversal of the antiplatelet effects of ticagrelor&#xD;
      within 5 minutes of the initiation of infusion that is sustained for 20-24 hours.&#xD;
&#xD;
      In subjects with potential drug interaction from recent concomitant use of moderate or strong&#xD;
      CYP3A inhibitors with ticagrelor, an alternative regimen may be used comprising&#xD;
      administration of 36 g over an active treatment period of 24 hours and 10 min. (This&#xD;
      alternative regimen will be an initial 12 g bolus infusion over 10 minutes, followed&#xD;
      immediately by a loading infusion of 12 g over 6 hours which will then be followed by a&#xD;
      maintenance regimen of 12 g infused over 18 hours for a total infusion of 36 grams over 24&#xD;
      hours and 10 minutes).&#xD;
&#xD;
      All subjects may be discharged from the clinical site between Days 3 and 7 inclusive and will&#xD;
      return for a Follow-up visit on Day 7, if already discharged, and on Day 35 (± 3 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal - Platelet Reactivity Units (PRU)</measure>
    <time_frame>4 hours post-initiation of infusion</time_frame>
    <description>Minimum % inhibition of PRU within 4 hours of the initiation of study drug as assessed by VerifyNow™ PRUTest™ platelet function assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis - Uncontrolled major of life-threatening bleeding - Achievement</measure>
    <time_frame>4 hours post-initiation of infusion</time_frame>
    <description>Achievement of effective (graded as good or excellent) hemostasis following initiation of infusion will be centrally adjudicated using prespecified criteria for effective hemostasis for visible and non-visible major bleeding [Scale (from best to worst) measured as: Excellent, Good, Poor/None]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis - Urgent surgery or invasive procedure - Achievement</measure>
    <time_frame>4 hours post-initiation of infusion</time_frame>
    <description>Achievement of effective hemostasis following initiation of infusion will be centrally adjudicated using prespecified criteria for effective hemostasis derived from the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) clinical bleeding scale [GUSTO scale (from best to worst): Effective (no bleeding, mild bleeding or moderate bleeding) or Not effective (severe bleeding)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum % inhibition of Platelet Reactivity Index (PRI) (VASP)</measure>
    <time_frame>4 hours post-initiation of infusion</time_frame>
    <description>Minimum % inhibition of PRI assessed by VASP within 4 hours after the initiation of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum reversal of PRU assessed by VerifyNow™ PRUTest™</measure>
    <time_frame>4 hours post-initiation of infusion</time_frame>
    <description>Maximum reversal of PRU assessed by VerifyNow™ PRUTest™ within 4 hours after the initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum reversal of PRI assessed by VASP</measure>
    <time_frame>4 hours post-initiation of infusion</time_frame>
    <description>Maximum reversal of PRI assessed by VASP within 4 hours after the initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving reversal of platelet inhibition of ticagrelor using PRU and PRI - 60%</measure>
    <time_frame>Any time point between infusion initiation and Day 3 (Pre-dose, 5-10 minutes, 30+5 minutes, 1+0.25 hours, 4+0.25 hours, 12+0.5 hours, 24+1 hours, and Day 3)</time_frame>
    <description>Proportion of subjects achieving 60% reversal of platelet inhibition of ticagrelor using PRU and PRI at any time point during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving reversal of platelet inhibition of ticagrelor using PRU and PRI - 80%</measure>
    <time_frame>Any time point between infusion initiation and Day 3 (Pre-dose, 5-10 minutes, 30+5 minutes, 1+0.25 hours, 4+0.25 hours, 12+0.5 hours, 24+1 hours, and Day 3)</time_frame>
    <description>Proportion of subjects achieving 80% reversal of platelet inhibition of ticagrelor using PRU and PRI at any time point during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving reversal of platelet inhibition of ticagrelor using PRU and PRI - 100%</measure>
    <time_frame>Any time point between infusion initiation and Day 3 (Pre-dose, 5-10 minutes, 30+5 minutes, 1+0.25 hours, 4+0.25 hours, 12+0.5 hours, 24+1 hours, and Day 3)</time_frame>
    <description>Proportion of subjects achieving 100% reversal of platelet inhibition of ticagrelor using PRU and PRI at any time point during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of at least 60% reversal by PRU and PRI</measure>
    <time_frame>Any time point between infusion initiation and Day 3 (Pre-dose, 5-10 minutes, 30+5 minutes, 1+0.25 hours, 4+0.25 hours, 12+0.5 hours, 24+1 hours, and Day 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of at least 80% reversal by PRU and PRI</measure>
    <time_frame>Any time point between infusion initiation and Day 3 (Pre-dose, 5-10 minutes, 30+5 minutes, 1+0.25 hours, 4+0.25 hours, 12+0.5 hours, 24+1 hours, and Day 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of at least 100% reversal by PRU and PRI</measure>
    <time_frame>Any time point between infusion initiation and Day 3 (Pre-dose, 5-10 minutes, 30+5 minutes, 1+0.25 hours, 4+0.25 hours, 12+0.5 hours, 24+1 hours, and Day 3)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Urgent Surgery</condition>
  <condition>Invasive Procedure</condition>
  <arm_group>
    <arm_group_label>Bentracimab (PB2452) Infusion - Open Label Active Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. Patients with uncontrolled major or life-threatening bleeding.&#xD;
Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. For patients in need of urgent surgery or invasive procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bentracimab (PB2452) Infusion</intervention_name>
    <description>Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.&#xD;
In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion</description>
    <arm_group_label>Bentracimab (PB2452) Infusion - Open Label Active Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be eligible for inclusion into the study if they meet all of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Male or female &gt;18 years of age with documented or verbal informed consent&#xD;
&#xD;
               2. History or documentation of ticagrelor intake within the prior 3 days&#xD;
&#xD;
               3. Patients described below who require urgent reversal of the antiplatelet effects&#xD;
                  of ticagrelor:&#xD;
&#xD;
        Patients with uncontrolled major or life-threatening bleeding, requiring urgent reversal of&#xD;
        the antiplatelet effects of ticagrelor. It is expected that enrolled patients would have&#xD;
        characteristics similar to those described below:&#xD;
&#xD;
          -  Potentially life-threatening bleeding with signs or symptoms of hemodynamic&#xD;
             compromise, e.g., systolic blood pressure &lt; 90 mm Hg and signs or symptoms of low&#xD;
             cardiac output not otherwise explained&#xD;
&#xD;
          -  Bleeding in a critical organ or closed space, such as intracranial, intraspinal,&#xD;
             intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular bleed&#xD;
             with compartment syndrome&#xD;
&#xD;
          -  Visible, uncontrolled bleeding associated with a corrected hemoglobin level &lt; 8.0&#xD;
             g/dL, a fall in hemoglobin level of ≥ 2.0 g/dL (1.24 mmol/L) from a known baseline, or&#xD;
             requirement for transfusion of 2 or more units of packed red blood cells (PRBC)&#xD;
&#xD;
        Patients requiring urgent surgery or invasive procedure when it is not medically advisable&#xD;
        either to proceed urgently with impaired hemostasis or to delay the urgent procedure for 3&#xD;
        or more days as directed by ticagrelor labeling due to the high risk of bleeding. These&#xD;
        patients may typically be in any of the following clinical situations:&#xD;
&#xD;
          -  Requires urgent surgery or invasive procedure known to be associated with a risk of&#xD;
             significant bleeding (such as cardiac surgery, neurosurgery, or major orthopedic&#xD;
             surgery)&#xD;
&#xD;
          -  Requires urgent surgery or invasive procedure that may have an adverse procedural&#xD;
             outcome if hemostasis is impaired (such as neurological, spinal, ophthalmological,&#xD;
             urological, or orthopedic surgery)&#xD;
&#xD;
          -  At risk of experiencing life-threatening events, such as, shock, myocardial&#xD;
             infarction, or stroke, if significant intraoperative or postoperative bleeding occurs&#xD;
             (such as in elderly patients or patients with underlying cardiac or pulmonary disease&#xD;
             who have limited cardiopulmonary reserve)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known sensitivity or contraindication to PB2452 or any of its excipients&#xD;
&#xD;
          2. Patients in whom ticagrelor reversal is not considered urgent, e.g., patients with&#xD;
             stable or non-acute conditions who have low hemoglobin due to chronic, low-grade&#xD;
             gastrointestinal bleeding or who have stable, remote, or asymptomatic intracranial&#xD;
             hemorrhage&#xD;
&#xD;
          3. Patients expected to be clinically unsalvageable, such as, patients with intracranial&#xD;
             hemorrhage with Glasgow Coma Scale ≤ 8, or an intracerebral hematoma volume &gt; 60 cc or&#xD;
             patients with overwhelming sepsis&#xD;
&#xD;
          4. Any condition which, in the opinion of the investigator, would make it unsafe or&#xD;
             unsuitable for the patients to participate in this study. This includes assessment of&#xD;
             likelihood to cooperate with study follow-up visits and procedures&#xD;
&#xD;
             • Known pregnancy may be exclusionary in some regions or countries as directed by&#xD;
             national health authorities and/or local IRBs/Ethics Committees&#xD;
&#xD;
          5. Known use of clopidogrel, prasugrel or ticlopidine within 5 days of study drug&#xD;
             administration; known use of antiplatelet GPIIb/IIIa inhibitors, or cangrelor within 5&#xD;
             half-lives of expected study drug administration; or known use of warfarin,&#xD;
             rivaroxaban, apixaban, or edoxaban within 5 half-lives or expected study drug&#xD;
             administration&#xD;
&#xD;
          6. Known recent use (&lt; 5 day) of vitamin K, prothrombin complex concentrate, recombinant&#xD;
             factor VIIa, whole blood or plasma transfusions, idarucizumab, or andexanet-alfa&#xD;
             (coagulation factor Xa (recombinant), inactivated-zhzo)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak Bhatt, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital, Division of Cardiovascular Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>888-521-2805</phone>
    <email>Clinicaltrials@phasebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence St. Jude Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Diosdado</last_name>
      <phone>714-446-5177</phone>
      <email>Maria.Diosdado@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Harry Peled, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Moriarty, MSN, RN</last_name>
      <phone>202-877-3657</phone>
      <email>Theresa.m.moriarty@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Munish Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Ebreo</last_name>
      <phone>904-202-7063</phone>
      <email>Nancy.ebreo@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Hanel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Franchi, MD</last_name>
      <phone>904-244-2060</phone>
      <email>francesco.franchi@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Francesco Franchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intercoastal Medical Group, Inc.</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanette Wilson</last_name>
      <phone>941-404-4390</phone>
      <email>jewilson@intercoastalmedical.com</email>
    </contact>
    <investigator>
      <last_name>Mauricio Concha, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Fairfield</last_name>
      <phone>319-384-8335</phone>
      <email>Catherine-fairfield@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Dana King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Isaacs</last_name>
      <phone>859-323-4738</phone>
      <email>Jennifer.isaacs@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmed Abdel-Latif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner LSU Health Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela P. Cornelius, MD, FACEP</last_name>
      <phone>318-626-2325</phone>
      <email>acorne@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Angela P. Cornelius, MD, FACEP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>White Oak Medical Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Rongione, MD</last_name>
      <phone>202-524-4200</phone>
      <email>arongione@verizon.net</email>
    </contact>
    <investigator>
      <last_name>Anthony Rongione, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital, Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Clark, MD</last_name>
      <phone>248-898-3080</phone>
      <email>Carol.Clark@beaumont.edu</email>
    </contact>
    <investigator>
      <last_name>Carol Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Kansas City Hospital</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Kruger-Sargent</last_name>
      <phone>816-691-5373</phone>
      <email>dianne.kruger-sargent@nkch.org</email>
    </contact>
    <investigator>
      <last_name>Zafir Hawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cox Medical Centers</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Ratcliff, MS, CCRC</last_name>
      <phone>417-631-0214</phone>
      <email>Jessica.Ratcliff@coxhealth.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Woods, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Mainhart</last_name>
      <phone>910-279-1703</phone>
      <email>farmera@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Stahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Heart Center at Southeastern Health</name>
      <address>
        <city>Lumberton</city>
        <state>North Carolina</state>
        <zip>28358</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Herzog, MD</last_name>
      <phone>910-272-7241</phone>
      <email>William.herzog@duke.edu</email>
    </contact>
    <investigator>
      <last_name>William Herzog, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Hustad</last_name>
      <phone>701-417-2002</phone>
      <email>leah.hustad@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Mentor Ahmeti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Clinical Research Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Merritt, MSN, RN-BC</last_name>
      <phone>918-744-3426</phone>
      <email>Stacie.merritt@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Michael Charles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crozer Chester Medical Center</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Maxwell, PhD</last_name>
      <phone>844-464-6387</phone>
      <email>cmaxwell@gnineurol.org</email>
    </contact>
    <investigator>
      <last_name>Mandy Binning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JPS Health Network</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Max Masuda</last_name>
      <phone>817-702-6746</phone>
      <email>MMasuda@jpshealth.org</email>
    </contact>
    <investigator>
      <last_name>Angela Cornelius, MD, FACEP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Ottakring 3rd Med Dept, Cardiology and Intensive Care Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Huber, MD</last_name>
      <phone>(+43) 1 49 150 2301</phone>
      <email>kurt.huber@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Kurt Huber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Algemeen Stedelijk Ziekenhuis (ASZ) Study Center Cardiology</name>
      <address>
        <city>Aalst</city>
        <state>East Flanders</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Vanduynhoven, MD</last_name>
      <phone>+ 32 053 76 67 30</phone>
      <email>philippe.vanduynhoven@asz.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Vanduynhoven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg Study Center Intensive Care</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Van Boxstael, MD</last_name>
      <phone>+ 32 89 327100</phone>
      <email>sam.vanboxstael@zol.be</email>
    </contact>
    <investigator>
      <last_name>Sam Van Boxstael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV Poli Cardiologie</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Buysschaert, MD</last_name>
      <phone>(+32) 50 45 38 96</phone>
      <email>ian.buysschaert@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Ian Buysschaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp Cardiology Department - Clinical Trials</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Claeys, MD</last_name>
      <phone>(+32) 38 213000</phone>
      <email>marc.claeys@uantwerpen.be</email>
    </contact>
    <investigator>
      <last_name>Marc Claeys, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Hospital Hartcentrum Hasselt Research Center</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Vranckx, MD</last_name>
      <phone>(+32) 11 309393</phone>
      <email>pascal.vranckx@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Pascal Vranckx, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven, Universitair Ziekenhuis Leuven Dienst Bloedings- en Vaatziekten</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Vandenbriele, MD</last_name>
      <phone>(+32) 163 41 463</phone>
      <email>christophe.vandenbriele@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Christophe Vandenbriele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Manasterski</last_name>
      <phone>403-210-8548</phone>
      <email>Linda.manasterski@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Alexander J Gregory, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Brown, MD</last_name>
      <phone>506-648-7614</phone>
      <email>cdbrown@nbnet.nb.ca</email>
    </contact>
    <investigator>
      <last_name>Craig Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shamir Mehta, MD</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>40631</phone_ext>
      <email>smehta@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Shamir Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Phelan</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>3403</phone_ext>
      <email>Rachel.Phelan@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Tarit Saha, MBBS, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York PCI Group, Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren Cantor, MD</last_name>
      <phone>905-235-5966</phone>
      <email>cantorw@rogers.com</email>
    </contact>
    <investigator>
      <last_name>Warren Cantor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oakville Trafalgar Memorial Hospital</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 0L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adic Perez, MD</last_name>
      <phone>(905)845-2571</phone>
      <phone_ext>4154</phone_ext>
      <email>adperez@haltonhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Michael Heffernan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Crowe</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>10656</phone_ext>
      <email>SCrowe@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Marc Ruel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital, Unity Health Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mazer, MD, FRCPC</last_name>
      <phone>416-864-5825</phone>
      <email>david.mazer@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>David Mazer, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence Yau, MD</last_name>
      <phone>416-340-4074</phone>
      <email>Terry.yau@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Terrence Yau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois Tanguay, MD</last_name>
      <phone>514-376-3330</phone>
      <email>jean-francois.tanguay@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Jean-Francois Tanguay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Quebec - Universite Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Voisine, MD</last_name>
      <phone>418-656-4717</phone>
      <email>pierre.voisine@fmed.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Pierre Voisine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille Service USIC, Institut Coeur Poumon</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Lemesle, MD</last_name>
      <phone>(+33) 3 20 44 53 30</phone>
      <email>gilles.lemesle@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Lemesle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique-Hopitaux de Paris (AP-HP) Pitie-Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Montalescot, MD</last_name>
      <phone>(+33) 1 42 16 30 06</phone>
      <email>gilles.montalescot@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Montalescot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat Hospital, Service de Cardiologie</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Steg, MD</last_name>
      <phone>(+33) 140258669</phone>
      <email>gabriel.steg@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Steg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers, Centre Cardio-Vasculaire</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Bouleti, MD</last_name>
      <phone>+33 (0) 3-80-29-33-46</phone>
      <email>claire.bouleti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Claire Bouleti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hopital Trousseau Service de Cardiologie-USCI 2 eme etage</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Angoulvant, MD</last_name>
      <phone>(+33) 247479054</phone>
      <email>d.angoulvant@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Angoulvant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma Cardiologia</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego Ardissino, MD</last_name>
      <phone>(+39) 0521702070</phone>
      <email>dardissino@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Diego Ardissino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7512 KZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens von Birgelen, MD</last_name>
      <phone>(+31) 534872105</phone>
      <email>cre@mst.nl</email>
    </contact>
    <investigator>
      <last_name>Clemens von Birgelen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurrien M Ten Berg, MD</last_name>
      <phone>(+31) 883203000</phone>
      <email>jurtenberg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jurrien M Ten Berg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Vazquez Rodriguez, MD</last_name>
      <phone>(+34) 981178342</phone>
      <email>jose.manuel.vazquez.rodriguez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Jose Manuel Vazquez Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Barrabes, MD</last_name>
      <phone>(+34) 932746000</phone>
      <phone_ext>6396</phone_ext>
      <email>jabarrabes@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Jose Barrabes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre, Residencia general</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Jose Bueno Zamora, MD</last_name>
      <phone>(+34) 913908519</phone>
      <email>hector.bueno@cnic.es</email>
    </contact>
    <investigator>
      <last_name>Hector Jose Bueno Zamora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos - Instituto Cardiovascular (ICV)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis David Vivas Balcones, MD</last_name>
      <phone>(+34) 913303149</phone>
      <email>dvivas@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Luis David Vivas Balcones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vírgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Temboury, MD</last_name>
      <phone>(+34) 649461625</phone>
      <email>francisco.temboury.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Francisco Temboury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Jesus Hidalgo Urbano, MD</last_name>
      <phone>(+34) 629987772</phone>
      <email>rjhidalur@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Rafael Jesus Hidalgo Urbano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital, Department of Cardiology</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Erlinge, MD</last_name>
      <phone>(+46) 733746165</phone>
      <email>david.erlinge@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Erlinge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Region Uppsala, Akademiska Hospital Cardio and Pulmonary Medicine and Clinical Physiology</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sevcik, MD</last_name>
      <phone>(+46) 720 341 372</phone>
      <email>robert.sevcik@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Robert Sevcik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Basel Department of Cardiology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Mueller, MD</last_name>
      <phone>(+41) 61 3286549</phone>
      <email>christian.mueller@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Valgimigli</last_name>
      <phone>(+41) 918053347</phone>
      <email>marco.valgimigli@cardiocentro.org</email>
    </contact>
    <investigator>
      <last_name>Marco Valgimigli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East and North Hertfordshire, NHS Trust, Lister Cardiac Research Office, Cardiology Green Zone, Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <state>Hertfordshire</state>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diana Gorog, MD</last_name>
      <phone>+44 (0) 1438 284379</phone>
      <email>d.gorog@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Diana Gorog, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals, NHS Foundation Trust, Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Storey, MD</last_name>
      <phone>(+44) 1142266159</phone>
      <email>r.f.storey@sheffield.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Storey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

